Sanofi, GSK coronanvirus vaccine to get up to $2.1 billion from U.S. government

U.S. listed shares of Sanofi SNY, -0.90% gained 0.8% in premarket trading on Friday after it said the U.S. government will pay up to $2.1 billion for the COVID-19 vaccine candidate it is developing with GlaxoSmithKline GSK, -0.22%. The GSK stock listed in the U.S. was up 1.2% before the market opened. The funding, part of Operation Warp Speed, will be used to support ongoing clinical development and manufacturing of the experimental candidate, with at least 100 million doses promised to the U.S. The U.S. government has already said it...